5-azacitidine and Thalidomide for patients with Myelodysplastic Syndromes to assess safety and efficacy

Trial Profile

5-azacitidine and Thalidomide for patients with Myelodysplastic Syndromes to assess safety and efficacy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Azacitidine (Primary) ; Thalidomide (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Apr 2018 Results assessing genetic biomarkers following treatment with Azacitidine or Thalidomide or Lenalidomide that predict clinical outcomes in MDS in patients enrolled in ALLG MDS3 and MDS4 clinical trials, were presented at the 109th Annual Meeting of the American Association for Cancer Research.
    • 18 May 2017 Status changed from active, no longer recruiting to completed.
    • 25 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top